Bryan Garnier - Inditex (ITX SM) (ITX SM) INDITEX: Q1 results: sales miss but top line trends already improved in the first half of Q2 | BUY | Under Review

Report

Bryan Garnier

Cedric Rossi

INDITEX: Q1 results: sales miss but top line trends already improved in the first half of Q2 | BUY | Under Review

INDITEX - BUY | Under Review
Q1 results: sales miss but top line trends already improved in the first half of Q2

Q1 sales miss due to unfavourable weather conditions...
... but margins beat CS expectations
Inventory levels remained under control (+1%)
FY guidance confirmed as Q2 trends improved significantly

12/06/2019 3 EN

Underlying

Inditex (ITX SM)

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports on these Companies

Sabadell

INDITEX: 1Q’25 RESULTS (ANÁLISIS BANCO SABADELL)

1Q'25 vs. 1Q'24 Results Sales: € 8.274 Bn (+1.5% vs. +3.1% BS(e) and +2.8% consensus); EBIT: € 1.641 Bn (+0.3% vs. +1.8% BS(e) and +0.9% consensus); Net Profit: € 1.305 Bn (+0.9% vs. +0.8% BS(e) and +0.8% consensus);

EUR 100.00

June 11, 2025 June 11, 2025 1 EN

Sabadell

INDITEX: RDOS. 1T’25 (ANÁLISIS BANCO SABADELL)

Rdos. 1T'25 vs 1T'24: Ventas: 8.274 M euros (+1,5% vs +3,1% BS(e) y +2,8% consenso); EBIT: 1.641 M euros (+0,3% vs +1,8% BS(e) y +0,9% consenso); BDI: 1.305 M euros (+0,9% vs +0,8% BS(e) y +0,8% consenso).

EUR 100.00

June 11, 2025 June 11, 2025 1 ES

Sabadell

IBERIAN DAILY 11 JUNE (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: CHANGES IBEX 35, INDITEX, SACYR. Flat stock markets Stock markets remained calm, awaiting relevant macroeconomic data (May’s inflation will be released today in the US) or newsflow on the negotiations with China. In the STOXX 600, the best-performing sectors were Autos and Energy, whereas Banks and Financial Services ended with the biggest drops. On the macro side, in the euro zone, June’s Sentix index climbed more than expected to the highest level in one year, also providing the first positive reading in 2025. In the US, the NFIB SMEs confidence rose more than expected, puttin...

EUR 100.00

June 11, 2025 June 11, 2025 1 EN

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

19h / 25m 19h / 25m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: financing package update

Yesterday, Avantium announced it had reached a conditional agreement with ABN AMRO, ASN, ING, Invest-NL and Rabobank to extend and amend its senior debt facility agreement, representing up to EUR125.1m as of December 2024. As such, (i) the remaining EUR14.1m debt commitment would be cancelled in ex

August 13, 2025 August 13, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

August 12, 2025 August 12, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

INDITEX: Q1 results: sales miss but top line trends already improved in the first half of Q2 | BUY | Under Review

INDITEX: 1Q’25 RESULTS (ANÁLISIS BANCO SABADELL)

INDITEX: RDOS. 1T’25 (ANÁLISIS BANCO SABADELL)

IBERIAN DAILY 11 JUNE (ANÁLISIS BANCO SABADELL)

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

Avantium: financing package update

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe